Mechanisms of Extracellular-Vesicle Signaling During Progressive Critical Organ Dysfunction

Abstract

Extracellular vesicles (EVs) have emerged as pivotal mediators of intercellular communication, exerting profound effects on organ function and systemic homeostasis. Increasing evidence implicates EVs in the pathogenesis and progression of critical organ dysfunction, especially in the context of sepsis, acute respiratory distress syndrome, and multi-organ failure. This review synthesizes recent scientific advances elucidating the molecular mechanisms of EV-mediated signaling, explores their contributions to disease burden, highlights clinically relevant risk factors and features, and discusses diagnostic, therapeutic, and guideline-driven approaches. The translational implications for monitoring, prognosis, and targeted interventions are critically appraised, underscoring future directions for clinical application.

Introduction

Critical organ dysfunction, a hallmark of conditions such as sepsis, trauma, and acute organ injuries, remains a leading cause of mortality in the intensive care setting. The pathophysiology involves complex, multi-layered communication between cells and organs. Extracellular vesicles—comprising exosomes, microvesicles, and apoptotic bodies—have gained recognition as major conveyors of biological information, capable of modulating inflammation, immune responses, coagulation, and tissue repair. Understanding the mechanistic roles of EVs in progressive organ dysfunction is vital for developing diagnostic and therapeutic strategies that can improve patient outcomes.

Epidemiology / Disease Burden

Organ dysfunction in critically ill patients, including acute kidney injury (AKI), acute liver failure, and acute respiratory distress syndrome (ARDS), affects millions worldwide each year. Mortality rates remain high, particularly in multi-organ failure, where up to 60% of affected patients may succumb despite advances in supportive care. The recognition that EVs participate in these pathologies has prompted significant research into their epidemiological impact and potential as disease biomarkers. Studies have documented elevated circulating EV levels in patients with sepsis, ARDS, and other critical illnesses, correlating with disease severity and outcomes. The burden extends beyond the acute phase, as survivors may experience long-term sequelae attributed in part to persistent EV-mediated signaling disturbances.

Pathophysiology

EVs are lipid-bilayer-enclosed particles released by virtually all cell types under physiological and pathological conditions. Their cargo—comprising proteins, lipids, mRNA, microRNA, and DNA fragments—reflects the state of the parent cell and modulates recipient cell function. In critical organ dysfunction, stressed or injured endothelial cells, leukocytes, and platelets release EVs enriched in pro-inflammatory and pro-coagulant mediators. These EVs propagate vascular inflammation, activate the coagulation cascade, and alter microvascular permeability, thereby exacerbating tissue injury. For example, EVs bearing tissue factor promote disseminated intravascular coagulation in sepsis, while those carrying mitochondrial DNA can trigger innate immune responses and amplify cytokine release. Furthermore, organ-specific EVs may traffic signals between distant tissues, perpetuating a maladaptive systemic response. Recent studies utilizing proteomics and transcriptomics have delineated distinct EV signatures associated with various stages of organ dysfunction, providing mechanistic insights and potential therapeutic targets.

Risk Factors

Several patient- and disease-related factors influence the production, release, and pathogenicity of EVs during critical illness. Established risk factors include advanced age, pre-existing comorbidities (such as chronic kidney or liver disease), the severity of the initial insult (e.g., high pathogen load in sepsis), and genetic predispositions influencing inflammatory and coagulant pathways. Iatrogenic factors, including mechanical ventilation and exposure to nephrotoxic or hepatotoxic drugs, may further augment EV release. Understanding these risk factors is essential for identifying at-risk populations, stratifying prognosis, and tailoring monitoring strategies.

Clinical Features

The clinical manifestations of EV-mediated organ dysfunction are heterogeneous, reflecting the diverse roles of EVs in inflammation, coagulation, and cellular apoptosis. Common features include rapid progression of organ-specific symptoms—such as oliguria in AKI, hypoxemia in ARDS, or jaundice in liver failure—accompanied by systemic findings of shock, coagulopathy, and altered mental status. Elevated levels of circulating EVs have been associated with worse clinical trajectories, higher Sequential Organ Failure Assessment (SOFA) scores, and increased mortality. In certain contexts, the detection of EVs with specific surface markers or cargo profiles may offer early warning of impending decompensation.

Diagnosis

Traditionally, organ dysfunction is diagnosed based on clinical criteria and laboratory markers, such as creatinine for AKI or PaO2/FiO2 ratios for ARDS. However, these methods lack sensitivity and specificity for early detection and prognostication. EVs represent a promising class of biomarkers, with several studies demonstrating that quantification and characterization of circulating EVs can distinguish between disease states and predict outcomes. Advanced techniques including nanoparticle tracking analysis, flow cytometry, and high-throughput omics have enabled detailed profiling of EV populations. Integration of EV-based diagnostics into clinical practice remains challenging due to technical limitations and the need for standardization, but ongoing research aims to address these barriers.

Treatment & Management

Management of critical organ dysfunction centers on supportive care, addressing underlying etiologies, and mitigating secondary injury. While no EV-targeted therapies are currently approved for clinical use, preclinical studies suggest that interventions modulating EV release or function may attenuate organ injury. Strategies under investigation include pharmacologic inhibition of EV biogenesis pathways (e.g., neutral sphingomyelinase inhibitors), immunomodulation to alter EV cargo, and extracorporeal removal of pathogenic EVs using hemofiltration techniques. Additionally, engineered EVs loaded with protective factors are being explored as therapeutic vectors to promote tissue repair and modulate immune responses.

Recent Advances / Emerging Therapies

Recent years have witnessed substantial progress in understanding EV biology and translational potential. Notable advances include the identification of EV-associated microRNAs as regulators of endothelial and immune cell function, and the development of next-generation sequencing approaches to profile EV content at single-vesicle resolution. Clinical trials are underway to assess the safety and efficacy of EV-based diagnostics and therapeutics in sepsis, ARDS, and other critical conditions. Moreover, efforts to standardize EV isolation, quantification, and reporting are facilitating multicenter research and accelerating clinical adoption. Emerging therapies harnessing mesenchymal stem cell-derived EVs show promise in reducing inflammation and promoting repair in preclinical models of organ injury.

Guideline Recommendations

International guidelines for the management of critical illness, such as those from the Surviving Sepsis Campaign and the American Thoracic Society, currently do not include specific recommendations for EV-directed diagnostics or therapies. However, growing recognition of EVs as mediators and biomarkers of organ dysfunction is prompting calls for their inclusion in future guideline updates. Consensus statements emphasize the need for rigorous validation of EV assays, integration with established clinical parameters, and multidisciplinary collaboration to translate bench findings into bedside applications.

Conclusion

Extracellular vesicles are integral to the pathogenesis and progression of critical organ dysfunction, mediating complex signaling pathways that influence inflammation, coagulation, and tissue repair. Advances in EV research offer new avenues for early diagnosis, risk stratification, and targeted therapy. While challenges remain in standardization and clinical implementation, the evolving landscape of EV biology holds promise for transforming the management of critically ill patients and improving outcomes in organ dysfunction syndromes.